Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker XFOR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Matthew D. Perry | 10.72M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Coastlands Capital LLC | 10.72M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Coastlands Capital GP LLC | 10.72M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Coastlands Capital Partners LP | 10.72M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Coastlands Capital LP | 10.72M | 10.0% | SCHEDULE 13G/A ↗ |
| Oct 7, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Abigail P. Johnson | 4.56M | 4.6% | SCHEDULE 13G/A ↗ |
| Oct 7, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | FMR LLC | 4.56M | 4.6% | SCHEDULE 13G/A ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Bong Y. Koh | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Nimish Shah | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | VHCP Management EG, LLC | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | VHCP Management III, LLC | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | VHCP Co-Investment Holdings III, LLC | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Sep 21, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 5.56M | 5.6% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 8.09M | 8.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Joseph Edelman | 8.09M | 8.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Perceptive Advisors LLC | 8.09M | 8.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Deep Track Special Opportunities Fund, LP. | 1.12M | 1.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | David Kroin | 8.04M | 8.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 6.92M | 7.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Deep Track Capital, LP | 8.04M | 8.3% | SCHEDULE 13G/A ↗ |
| Jul 30, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | BlackRock, Inc. | 5.53M | 5.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 6.89M | 7.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Joseph Edelman | 6.89M | 7.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Perceptive Advisors LLC | 6.89M | 7.3% | SCHEDULE 13G/A ↗ |
| Mar 6, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Inception Trust | 4.52M | 5.2% | SCHEDULE 13G/A ↗ |
| Mar 6, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Morgan Stanley Investment Management Inc. | 8.88M | 10.2% | SCHEDULE 13G/A ↗ |
| Mar 6, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Morgan Stanley | 8.88M | 10.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Ortav Yehudai | 5.23M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Trails Edge Biotechnology Master Fund, LP | 5.23M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Trails Edge Capital Partners, LP | 5.23M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BCLS II Equity Opportunities, LP | 7.05M | 7.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BCLS I Investco, LP | 89,633 | 0.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BCLS II Investco, LP | 758,598 | 0.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BCIP Life Sciences Associates, LP | 7,817 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Bain Capital Life Sciences Fund II, L.P. | 64,190 | 0.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Bain Capital Life Sciences Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Xiaoying Tian | 6.43M | 7.4% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | XFOR X4 Pharmaceuticals, Inc. | Saturn V Capital Management LP | 6.43M | 7.4% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Mark N. Lampert | 3.41M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF Inc/Il | 3.41M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF Partners L P/Il | 3.41M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF GP Holdings LLC | 3.17M | 3.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF Partners OS Ltd. | 194,535 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Biotechnology Value Trading Fund OS LP | 194,535 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF II GP LLC | 1.34M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Biotechnology Value Fund II LP | 1.34M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | BVF I GP LLC | 1.83M | 2.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Biotechnology Value Fund L P | 1.83M | 2.1% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | XFOR X4 Pharmaceuticals, Inc. | Daniel Mack | 2.45M | 2.8% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances